We are live on ! Find out more
GEVA

SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA

Delisted

GEVA was delisted on the 22nd of June, 2015.

Back to rankings

0 hedge funds and large institutions have $0 invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2015 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 130 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 130 → 0 (-130)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $3.89B → $0 (-$3.89B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 130

Holders
–
Holders Change
-130
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
130
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$1.14B
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$541M
3
Capital Research Global Investors
Capital Research Global Investors
California
-$442M
4
CWAM
Columbia Wanger Asset Management
Illinois
-$317M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$152M
Name Holding Trade Value Shares
Change 		Change in
Stake
Canada Life
101
Canada Life
Manitoba, Canada
– -$207K -2,140 Closed
UBS Group
102
UBS Group
Switzerland
– -$208K -2,135 Closed
FAM
103
Fortaleza Asset Management
Illinois
– -$189K -1,935 Closed
SO
104
STRS Ohio
Ohio
– -$165K -1,700 Closed
Fifth Third Bancorp
105
Fifth Third Bancorp
Ohio
– -$149K -1,532 Closed
PG
106
PEAK6 Group
Illinois
– -$148K -1,515 Closed
SG Americas Securities
107
SG Americas Securities
New York
– -$114K -1,168 Closed
US Bancorp
108
US Bancorp
Minnesota
– -$110K -1,131 Closed
TRCT
109
Tower Research Capital (TRC)
New York
– -$108K -1,103 Closed
Teacher Retirement System of Texas
110
Teacher Retirement System of Texas
Texas
– -$75K -772 Closed
PAM
111
Panagora Asset Management
Massachusetts
– -$75K -766 Closed
BlackRock
112
BlackRock
New York
– -$59K -601 Closed
Zurich Cantonal Bank
113
Zurich Cantonal Bank
Switzerland
– -$58K -599 Closed
BNP Paribas Financial Markets
114
BNP Paribas Financial Markets
France
– -$46.4K -476 Closed
SEI Investments
115
SEI Investments
Pennsylvania
– -$45K -462 Closed
Royal Bank of Canada
116
Royal Bank of Canada
Ontario, Canada
– -$38K -390 Closed
RFC
117
Russell Frank Company
Washington
– -$29K -296 Closed
BJ
118
BlackRock Japan
Japan
– -$21K -218 Closed
CFA
119
CT Financial Advisors
Pennsylvania
– -$19.5K -200 Closed
IWMPD
120
Integrated Wealth Management (Palm Desert)
California
– -$19K -200 Closed
Federated Hermes
121
Federated Hermes
Pennsylvania
– -$18K -183 Closed
HI
122
Hudock Inc
Pennsylvania
– -$12K -125 Closed
DADC
123
D.A. Davidson & Co
Montana
– -$9K -100 Closed
WA
124
Waverly Advisors
Alabama
– -$10K -100 Closed
CHP
125
Cable Hill Partners
Oregon
– -$7K -67 Closed
2 3 4
5
6

GEVA Hedge Fund Activity: Q2 2015 in Review

0 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q2 2015, worth a combined $0 — down 100% from $3.89B a quarter earlier.

Sellers outnumbered buyers: 130 funds closed out of GEVA and 0 opened new positions — a net loss of 130 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $1.14B sold.

  • 0 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q2 2015, down from 130 in Q1 2015.
  • Funds reported $0 of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q2 2015, down 100% quarter-over-quarter.
  • 0 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q2 2015 and 130 closed out, a net change of -130 holders.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q2 2015 was Baker Bros. Advisors, an estimated $1.14B sold.

Based on aggregated 13F filings for Q2 2015.